Ziopharm Oncology Inc (ZIOP) 13.38 $ZIOP 'Mad Money'

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ziopharm Oncology Inc (ZIOP) 13.38 $ZIOP

'Mad Money' Lightning Round: Sell, Sell, Sell Caesars Entertainment
at The Street - Fri Mar 06, 5:00AM CST
Cramer does not favor Control4, Ziopharm Oncology or Stratesys.
ZIOP: 13.38 (-0.43), SSYS: 62.34 (-1.97), CZR: 9.63 (-0.53), HPQ: 33.18 (-0.82), CTRL: 12.27 (-0.15)

3D Is Not The Place To Be - Cramer's Lightning Round (3/5/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 06, 4:49AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 5. Bearish Calls: Control4 Corp. (NASDAQ: CTRL ): "It is software for home entertainment, it is like no man! It's hard enough to be...
ZIOP: 13.38 (-0.43), VJET: 8.04 (-0.20), SSYS: 62.34 (-1.97), CZR: 9.63 (-0.53), HPQ: 33.18 (-0.82), CRM: 64.56 (-1.03), CTRL: 12.27 (-0.15)

Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?
at The Street - Thu Mar 05, 7:27PM CST
Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.
BID: 41.05 (-0.68), TSLA: 193.88 (-6.75), GWRE: 52.98 (-0.06), ZIOP: 13.38 (-0.43), GE: 25.42 (-0.40), LMT: 197.66 (-1.44), PCYC: 254.56 (+0.34), BX: 38.75 (-0.39), BMRN: 113.77 (+0.27), UTX: 119.43 (-1.36), HZO: 25.64 (+0.21), XOM: 85.63 (-1.11), CZR: 9.63 (-0.53), SBUX: 92.21 (-1.42), ETP: 57.31 (-0.74), SSYS: 62.34 (-1.97), RCPT: 140.09 (-1.10), COST: 149.54 (-1.63), ABBV: 55.64 (-1.22), TRAK: 40.21 (-0.51), ROL: 33.79 (-0.21), OA: 68.73 (+0.98), MOV: 23.86 (-0.59), MBLY: 37.84 (+0.82), CSCO: 28.92 (-0.38), URI: 90.50 (-1.56), CTRL: 12.27 (-0.15), AMZN: 380.09 (-7.74), GPRO: 40.13 (-0.95), KR: 74.35 (+0.04), WFC: 54.59 (-0.25), NXPI: 98.48 (-0.19), BMY: 65.12 (-0.93), BA: 153.12 (-1.35), HPQ: 33.18 (-0.82), DRI: 62.71 (-1.50), ISIS: 70.44 (-1.32), MCD: 97.13 (-1.98), CVX: 103.55 (-1.18), BABA: 84.40 (-1.70)

Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in   timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), LLY: 68.41 (-2.18), STML: 15.75 (-0.15)

This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), XON: 50.16 (+0.66)

Intrexon: Back-End Economics Could Generate Huge Upside
Chris Bunge - Seeking Alpha - Fri Feb 27, 11:20AM CST
"I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning." --Steve Jobs As an investor important characteristics of a company lie in the product or service they...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market
at The Street - Fri Feb 27, 5:30AM CST
BroadSoft, TG Therapeutics and Ziopharm Oncology also have room for further gains, according to a technical analysis of their recent stock activity.
ZIOP: 13.38 (-0.43), FEYE: 42.83 (-1.08), TGTX: 15.16 (-0.43), BSFT: 31.45 (-0.29)

Ziopharm reports 4Q loss
Automated Insights - Fri Feb 27, 4:13AM CST
NEW YORK (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $10.4 million in its fourth quarter.
ZIOP: 13.38 (-0.43)

ZIOPHARM Oncology beats by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 4:56PM CST

ZIOP: 13.38 (-0.43)

Bullish Traders Take Another Dose of Ziopharm Oncology
at The Street - Tue Feb 24, 4:45AM CST
Bullish option traders are back in Ziopharm Oncology.
ZIOP: 13.38 (-0.43)

What Investors Should Expect From Janet Yellen’s Testimony on Tuesday
at The Street - Mon Feb 23, 2:21PM CST
The CNBC 'Fast Money Halftime' trading panel take a look at how stocks are likely to respond to Fed chair Janet Yellen's Senate testimony on Tuesday.
USO: 18.24 (-0.47), ZIOP: 13.38 (-0.43), EWG: 29.04 (-0.47), UCO: 8.11 (-0.37), OIH: 34.14 (-0.83), NEM: 23.30 (-2.00), SLXP: 158.01 (+0.57), DXJS: 33.17 (-0.04), TLT: 123.50 (-2.79), DXJ: 54.54 (+0.35), SPY: 207.50 (-2.96), QQQ: 107.41 (-1.23), EWU: 18.54 (-0.42), DE: 90.26 (-0.20), DIA: 178.40 (-2.77), IWM: 121.17 (-1.55), XLE: 76.78 (-1.40)

ZIOPHARMA Oncology Inc. Analyst Coverage Initiated: Brief Report Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Feb 17, 6:00AM CST
ZIOPHARMA Oncology Inc. (NASDAQ: ZIOP) a biotechnology company, engaged in the discovery and development of cancer therapies based in Boston, MA was one of the most traded companies today on the NASDAQ. ZIOP reached a new 52 week high and closed at nearly $10/share, up from a 52 week low of $2.31 in October of 2014.
ZIOP: 13.38 (-0.43)

ZIOPHARM Oncology Announces Exercise of Option to Purchase Additional Shares
GlobeNewswire - Thu Feb 12, 6:36AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from the sale of the additional shares are expected to be approximately $13.1 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM, bringing the total gross proceeds from the offering to $100.6 million. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.
ZIOP: 13.38 (-0.43), JPM: 60.89 (-1.11)

InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST

ZIOP: 13.38 (-0.43), TROV: 6.20 (-0.09), CRR: 35.80 (-1.71), SLG: 123.54 (-4.37), WMS: 27.80 (+0.04), MLNK: 3.68 (+0.03), RXN: 27.24 (-0.31), KTWO: 19.33 (-0.68), PANW: 140.73 (-2.41), YHOO: 43.44 (-0.72), WHR: 203.42 (-7.40), UA: 74.80 (-0.99), GILD: 101.81 (-1.61), R: 91.48 (-2.38), SIX: 45.97 (-0.79), DATA: 92.34 (-3.16), TW: 129.11 (-2.40), MA: 90.79 (-2.02), NVET: 10.17 (-0.13), IPGP: 95.80 (-2.02)

Why Intrexon Corp's Shares are Up 14% Today
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Feb 10, 1:05PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of biotech billionaire Randal Kirk's flagship...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST

CAMT: 3.08 (-0.06), ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66), BIOC: 3.10 (-0.26), KKR: 23.71 (+0.04), NBG: 1.43 (-0.08), ARO: 4.04 (-0.01), ANFI: 10.28 (-0.92), HOT: 80.69 (-0.06), COUP: 9.77 (+0.10), URBN: 38.89 (+0.15), VSTM: 8.33 (+0.34), SYN: 2.45 (+0.10), ANTH: 6.12 (+0.59), SALE: 18.26 (+0.06), CGEN: 8.13 (-0.14), DF: 15.88 (-0.13), CJJD: 2.81 (-0.08), MERU: 2.36 (-0.27)

Intrexon and Ziopharm set for opening gaps
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:06AM CST

ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 3.11 (-0.10), BLUE: 113.14 (+0.91), ZIOP: 13.38 (-0.43), MYGN: 35.13 (+0.34), PSTI: 3.10 (-0.11), PFE: 33.97 (-0.50), XON: 50.16 (+0.66), TKMR: 18.76 (-0.93), ASPX: 69.14 (-0.32), MNKD: 5.47 (-0.26), HSP: 87.90 (+0.05), ZTS: 45.78 (-0.68), ANTM: 145.16 (-1.69), WMGI: 26.21 (-0.11), GILD: 101.81 (-1.61), MRK: 56.84 (-1.14), THOR: 39.50 (-0.83), TEVA: 56.40 (-0.11), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), ARNA: 4.32 (+0.09)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 25

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 86

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 0

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 21

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading

Top 5 Most Recently Viewed Articles

Apirone's Transformative Year: Innovations and Achievements

Updated Category News Views 120

Apirone's Transformative Year: Innovations and Achievements As we reflect on the recent progress made by Apirone, a leading cryptocurrency services provider, it is clear that 2025 marked a groundbreaking year in the company’s evolution. With a steadfast commitment to fostering innovation and enhancing user engagement, Apirone has undertaken a series of pivotal...

Continue Reading
Green Rain Energy Enhances Capital Structure with Share Swap

Updated Category News Views 170

Green Rain Energy Takes Strategic Steps to Strengthen Capital Structure Green Rain Energy Holdings Inc. (OTCID: GREH) has made an announcement that reflects its commitment to enhancing shareholder value and addressing market dynamics. The Chief Executive Officer, Alfredo Papadakis, plans to cancel 310 million common shares held through a holding company. This bold move...

Continue Reading
Piper Sandler's Positive View on Webster Financial's Potential

Updated Category News Views 92

Positive Insights from Piper Sandler on Webster Financial Piper Sandler has reaffirmed its Overweight rating on Webster Financial Corporation (NYSE: WBS), setting a steadfast price target of $54.00. This rating reflects confidence in the bank's potential for recovery and growth, despite recent challenges faced by the company. Current Performance Analysis Despite a...

Continue Reading
City Furniture's Grand Opening Sparks Growth in Tampa Region

Updated Category News Views 158

City Furniture Celebrates Exciting Grand Opening CITY Furniture, a leading home furnishings retailer, has celebrated the successful grand opening of its expansive 120,000-square-foot showroom in Sarasota. This event not only marks a significant milestone in the company's growth but also embodies its commitment to transforming the home shopping experience in the Tampa...

Continue Reading
Celebrating Scott Alexander Rose as a Pinnacle Achiever in 2024

Updated Category News Views 238

Scott Alexander Rose Recognized as a Pinnacle Achiever 2024 Scott Alexander Rose has been prominently featured and acknowledged as a Pinnacle Achiever 2024 for his exemplary contributions to education and philanthropy. His dedication reflects a lifetime of service and commitment to making a meaningful impact. A Commitment to Education and Excellence Dr. Rose's academic...

Continue Reading